Science Explorer Back to mapMap
Discussion
Institution · Evangelisches Krankenhaus Hamm

Most cited papers from Evangelisches Krankenhaus Hamm

Evangelisches Krankenhaus Hamm

What are the most cited papers from Evangelisches Krankenhaus Hamm?

The most cited paper from Evangelisches Krankenhaus Hamm is "Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)" (Michael G. Pfreundschuh et al., 2008), with 1,139 citations. Next come "First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial" (631) and "Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial" (422).

Showing 50 of 59 papers. Every paper with more than 28 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) Michael G. Pfreundschuh et al. · The Lancet Oncology 17 Jan 2008 1,139
2 First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial Barbara F. Eichhorst et al. · The Lancet Oncology 23 May 2016 631
3 Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial Michael Untch et al. · The Lancet Oncology 8 Feb 2016 422
4 Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) Benjamin Hanfstein et al. · Leukemia 26 Mar 2012 420
5 Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants for the SAKK and the German CML Study Group et al. · Leukemia Open access 14 Aug 2017 342
6 Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV Alice Charlotte Fabarius et al. · Blood 29 Oct 2011 291
7 Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD Richard F. Schlenk et al. · Blood Open access 18 Dec 2018 290
8 Cardiac Involvement in Churg-Strauss Syndrome Thomas E. Neumann, Bernhard Manger, Michael Schmid et al. · Medicine Jul 2009 264
9 Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease Maurizio Scarpa et al. · Orphanet Journal of Rare Diseases Open access 7 Nov 2011 237
10 Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia Roman Pfeifer et al. · Leukemia 5 Dec 2012 233
11 Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial Karolin Behringer et al. · The Lancet 21 Dec 2014 184
12 Intravascular Lithotripsy for Peripheral Artery Calcification Gunnar Tepe, Marianne Brodmann, Martin Werner et al. · JACC: Cardiovascular Interventions Open access Jun 2021 172
13 NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69–GeparSepto Michael Untch et al. · Journal of Clinical Oncology 13 May 2019 162
14 Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib Benjamin Hanfstein et al. · Leukemia 6 May 2014 139
15 Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib B. Hanfstein et al. · Haematologica Open access 16 May 2014 121
16 Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study) Barbara F. Eichhorst et al. · Blood 6 Dec 2014 117
17 Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials Othman Al‐Sawaf, Sandra Robrecht, Jasmin Bahlo et al. · Leukemia 17 Mar 2020 114
18 Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial Peter Paschka et al. · Leukemia 17 Apr 2018 107
19 A Combination of α-Fetoprotein and Des-γ-Carboxy Prothrombin Is Superior in Detection of Hepatocellular Carcinoma Judith Ertle, Dominik Heider, Marc Wichert et al. · Digestion 2013 106
20 Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer Martin Reck, Thomas Wehler, Francesco Orlandi et al. · Journal of Clinical Oncology Open access 27 May 2020 95
21 High-risk additional chromosomal abnormalities at low blast counts herald death by CML Rüdiger Hehlmann et al. · Leukemia Open access254 authors 7 May 2020 93
22 Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome®) Jörn-Hendrik Weitkamp, Christian Friedrich Poets, R. Sievers et al. · Infection 1998 87
23 Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML for the SAKK and the German CML Study Group et al. · Annals of Hematology 18 Sep 2015 81
24 Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy Matthias Kopp, Eckard H. Hamelmann, Meike Bendiks et al. · Pediatric Allergy and Immunology 25 Jun 2013 80
25 Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma Justin Z. Wang et al. · Nature Medicine Open access120 authors 21 Aug 2024 79
26 Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy Anna Kron et al. · Journal of Thoracic Oncology Open access 9 Dec 2020 71
27 Intravascular Lithotripsy for Peripheral Artery Calcification: Mid-term Outcomes From the Randomized Disrupt PAD III Trial Gunnar Tepe, Marianne Brodmann, William Bachinsky et al. · Journal of the Society for Cardiovascular Angiography & Interventions Open access 19 May 2022 68
28 Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis Stefan Früehauf, Julian Topaly, Eike C. Buss et al. · Cancer Open access 5 Mar 2007 68
29 De novo 13q deletions in two patients with mild anorectal malformations as part of VATER/VACTERL and VATER/VACTERL‐like association and analysis of EFNB2 in patients with anorectal malformations Gabriel C. Dworschak et al. · American Journal of Medical Genetics Part A 16 Aug 2013 66
30 Bilateral Acute Macular Neuroretinopathy After Vaccination Against SARS-CoV-2 Benedikt A. J. Book, Bárbara Schmidt, Andreas M. H. Foerster · JAMA Ophthalmology 21 Jul 2021 62
31 Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia German AML Cooperative Group, Wolfgang Kern, Gerhard Behre et al. · Cancer Open access 15 Jul 1998 62
32 Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Analysis Of The CLL10 Trial, An International, Randomized Study Of The German CLL Study Group (GCLLSG) Barbara F. Eichhorst et al. · Blood 15 Nov 2013 57
33 Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia Utz O. Krug et al. · Leukemia 9 Feb 2016 55
34 Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series Anke Thümler, Elke Miebach, Christina Lampe et al. · Journal of Inherited Metabolic Disease 23 Mar 2012 50
35 Contrast-Enhanced Ultrasound Algorithms (CEUS-LIRADS/ESCULAP) for the Noninvasive Diagnosis of Hepatocellular Carcinoma – A Prospective Multicenter DEGUM Study Barbara Schellhaas et al. · Ultraschall in der Medizin - European Journal of Ultrasound 14 Jul 2020 49
36 Long Term Follow‐up Data and Health‐Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG) Nadine Kutsch et al. · HemaSphere Open access 27 Jan 2020 46
37 Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia C. Zwick, Frank Hartmann, Samira Zeynalova et al. · Annals of Oncology Open access 3 Feb 2011 46
38 Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL Alexander Baraniskin, Roland Schroers · Cancers Open access 28 May 2021 45
39 Manual zur Indikation und Durchführung der Echokardiographie T. Buck, Ole A. Breithardt, Lothar Faber et al. · Clinical Research in Cardiology Supplements Apr 2009 44
40 Combined phacoemulsification and pars plana vitrectomy: Clear corneal versus scleral incisions Arnd Heiligenhaus, Alexa Holtkamp, Jörg Koch et al. · Journal of Cataract & Refractive Surgery Jun 2003 43
41 Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia N. Niederle, Dirk Megdenberg, Leopold Balleisen et al. · Annals of Hematology 22 Jan 2013 39
42 Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma Joerg Thomas Hartmann, Hans‐Georg Kopp, Viktor Gruenwald et al. · European Journal of Cancer 27 Nov 2019 38
43 High-Dose Versus Intermediate Dose Cytosine Arabinoside Combined with Mitoxantrone for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia: Results of an Age Adjusted Randomized Comparison Wolfgang Hiddemann, Carlo Aul, Georg Maschmeyer et al. · Leukemia & lymphoma/Leukemia and lymphoma 1993 38
44 Assessment of the Effect of Pharmacotherapy in Common Cold/Acute Bronchitis – the Bronchitis Severity Scale (BSS) Péter Kardos, S Lehrl, Wolfgang Kamin et al. · Pneumologie Open access 8 Jul 2014 36
45 Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG) Paula Cramer, Susanne Isfort, Jasmin Bahlo et al. · Haematologica ReviewOpen access 27 Aug 2015 36
46 Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review Lakshmi Nayak, Chetan Bettegowda, Florian Scherer et al. · Neuro-Oncology Open access 10 Apr 2024 35
47 Practice of dilatation after surgical correction in anorectal malformations Ekkehart Jenetzky et al. · Pediatric Surgery International 22 Sep 2012 34
48 Inheritance of the VATER/VACTERL association Enrika Bartels, Ekkehart Jenetzky, Benjamin D. Solomon et al. · Pediatric Surgery International Open access 11 May 2012 34
49 EPs 7630 is effective and safe in children under 6 years with acute respiratory tract infections: clinical studies revisited Wolfgang Kamin, Petra Funk, Georg Seifert et al. · Current Medical Research and Opinion 9 Nov 2017 32
50 A Handling Study to Assess Use of the Respimat ® Soft Mist™ Inhaler in Children Under 5 Years Old Wolfgang Kamin, Marion Frank, Sabine Kattenbeck et al. · Journal of Aerosol Medicine and Pulmonary Drug Delivery Open access 6 Apr 2015 32

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.